Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 27, 2020; 12(10): 766-774
Published online Oct 27, 2020. doi: 10.4254/wjh.v12.i10.766
Published online Oct 27, 2020. doi: 10.4254/wjh.v12.i10.766
Apatinib as an alternative therapy for advanced hepatocellular carcinoma
Xi-Hao Zhang, Xiu-Xiu Li, Ti Zhang, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Xi-Hao Zhang, Man-Qing Cao, Xiu-Xiu Li, Ti Zhang, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin 300060, China
Man-Qing Cao, Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Xiu-Xiu Li, Digestive Department, Shanxi Province Tumor Hospital, Taiyuan 030013, Shanxi Province, China
Ti Zhang, Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Author contributions: Zhang XH, Cao MQ and Li XX contributed to idea and design, literature search, and writing, review, and editing of the manuscript; all authors have read and approve the final manuscript.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ti Zhang, MD, Professor, Surgical Oncologist, Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, No. 24 Binshui Road, Tianjin 300060, China. zhangti@tjmuch.com
Received: February 27, 2020
Peer-review started: February 27, 2020
First decision: April 25, 2020
Revised: June 2, 2020
Accepted: August 15, 2020
Article in press: August 15, 2020
Published online: October 27, 2020
Peer-review started: February 27, 2020
First decision: April 25, 2020
Revised: June 2, 2020
Accepted: August 15, 2020
Article in press: August 15, 2020
Published online: October 27, 2020
Core Tip
Core Tip: Apatinib, as a tyrosine kinase inhibitor, has a good inhibitory effect on advanced hepatocellular carcinoma (HCC). In this article, we will introduce the role of apatinib in advanced HCC from the aspects of structure and mechanism, pharmacokinetics, preclinical studies, clinical trials, side effects, and combined drug use.